17 Feb 2021
NANETS COVID-19 Vaccination Position Statement
Given that neuroendocrine tumors are common among MEN patients, we’d like to highlight a recent COVID-19 vaccination position statement released by the North American Neuroendocrine Tumor Society (NANETS).
As a brief summary, NANETS supports COVID-19 vaccination for anyone who has had or currently has neuroendocrine neoplasms, assuming other reasons do not limit that person from receiving a vaccine. Neuroendocrine neoplasms include neuroendocrine tumors such as pancreatic neuroendocrine tumors, medullary thyroid carcinoma, and carcinoid tumors and neuroendocrine carcinomas. Additionally, they recommend prioritizing anyone who is actively receiving cancer treatments, has completed treatments in the last six months, or is expecting to be on treatment soon.
Below are links to the position statement as well as NANETS’s general information regarding COVID:
- NANETS full position statement regarding COVID-19 Vaccination and Neuroendocrine Tumor Patients
- General NANETS COVID-19 Resources
We have also updated AMEND USA’s COVID-19 website to reflect this position statement and would like to thank NANETS for providing a statement regarding COVID vaccination for those in our patient community who fall into this category.